Evidence map›Paper›PMID 37219054›Full record

ArticleFEBS open bio2023

Retraction statement: Shao, L., Zhang, X. and Yao, Q. (2020), The F-box protein FBXO11 restrains hepatocellular carcinoma stemness via promotion of ubiquitin-mediated degradation of Snail. FEBS Open Bio, 10: 1810-1820.

Abstract readRetraction Notice
In one paragraph

Article in FEBS open bio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

https://doi.org/10.1002/2211-5463.12933 The above article, published online on 13 July 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the between the authors, the Editor-in-Chief, FEBS Press, and John Wiley & Sons Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplications between this and articles either previously published or published in the same month [1-3]. Thus, the editors consider the conclusions of this manuscript substantially compromised. Reference 1 Wu H, He Y, Chen H, Liu Y, Wei B, Chen G, Lin H and Lin H LncRNA THOR increases osteosarcoma cell stemness and migration by enhancing SOX9 mRNA stability. doi: 10.1002/2211-5463.12620 2 Chen J, Wang P, Cai R, Peng H, Zhang C and Zhang M SLC34A2 promotes neuroblastoma cell stemness via enhancement of miR-25/Gsk3β-mediated activation of Wnt/β-catenin signaling. doi: 10.1002/2211-5463.12594 3 (2020) Long Non-Coding RNA THOR Enhances the Stem Cell-Like Traits of Triple-Negative Breast Cancer Cells Through Activating β-Catenin Signaling. Med Sci Monit 26, e923507.doi: 10.12659/MSM.923507.

Identifiers

PMID37219054
PMCPMC10392048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.